PGEN

Precigen, Inc. (NASDAQ:PGEN) investors will be delighted, with the company turning in some strong numbers with its latest results. Precigen outperformed estimates, with revenues of US$23m beating estimates by 12%. Statutory losses were US$0.02, 50% smaller thanthe analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Following the latest results, Precigen's three analysts are now forecasting revenues of US$124.6m in 2026. This would be a sizeable 295% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 94% to US$0.06. Before this latest report, the consensus had been expecting revenues of US$115.4m and US$0.10 per share in losses. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a considerable decrease in loss per share in particular. See our latest analysis for Precigen The consensus price target rose 16% to US$11.00, with the analysts encouraged by the higher revenue and lower forecast losses for next year. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing stands out from these estimates, which is that Precigen is forecast to grow faster in the future than it has in the past, with revenues expected to display 5x annualised growth until the end of 2026. If achieved, this would be a much better result than the 40% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 22% per year. So it looks like Precigen is expected to grow faster than its competitors, at least for a while. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the bus...

In the last week, the United States market has stayed flat, yet it has seen a remarkable 25% increase over the past year with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for continued success. Click here to see the full list of 187 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Aeluma, Inc. develops optoelectronic and electronic devices for sensing, communication, and computing applications in the United States with a market cap of $488.06 million. Operations: The company's revenue is primarily derived from its Semiconductor Equipment and Services segment, which generated $5.23 million. Insider Ownership: 25.8% Earnings Growth Forecast: 68.6% p.a. Aeluma is positioned for significant growth with forecasted revenue expansion of 77% annually, outpacing the US market. Despite a volatile share price and recent net losses, its strategic focus on high-growth sectors like AI infrastructure and quantum technologies is bolstered by substantial U.S. government contracts exceeding US$4 million. The company's innovative quantum dot laser platform, supported by NASA awards, enhances its competitive edge in photonics integration. However, low projected return on equity remains a concern. Click to explore a detailed breakdown of our findings in Aeluma's earnings growth report. Our valuation report here indicates Aeluma may be overvalued. Simply Wall St Growth Rating: ★★★★☆☆ Overview: STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses and accessory delivery systems for the eye, with a market cap of approximately $1.40 billion. Operations: The company's revenue is primarily generated from its ophthalmic surgical products, totaling $239.44 million. Insider Ownership: 26.2% Earnings Growth Forecast: 71.6% p.a. STAAR Surgical's growth potential is underscored by its forecasted revenue increase of 11.8% annually, slightly above the US market average. Recent earnings showed significant improvement with sales reaching US$93.52 million, a substantial rise from the previous year, and a shift to n...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. The significant revenue jump from $3.4 million to $21.6 million in Q1 2026 reflects the first full quarter of PAPZIMEOS availability and accelerating prescriber momentum. Management attributes rapid adoption to a broad FDA label that lacks surgical pre-requisites, allowing treatment across all disease severities. Strategic expansion into community practices now accounts for 25% of hub registrations, demonstrating the therapy's ease of administration beyond major academic centers. The launch is supported by a landmark expert position paper designating PAPZIMEOS as the preferred first-line standard of care over repeated surgical interventions. The therapy's mechanism of action, targeting the root cause of RRP via HPV-6 and HPV-11 immune response, provides a unique competitive advantage in a historically surgery-dependent market. Operational efficiency is driven by an established distribution infrastructure that allows for rapid integration into routine clinical workflows. Management expects to reach cash flow breakeven by the end of 2026, supported by PAPZIMEOS revenue growth and current cash reserves without seeking additional capital. The implementation of a permanent J-code on April 1, 2026, is expected to simplify claims processing and further accelerate patient access in Q2 and beyond. Clinical expansion plans include initiating a pediatric trial for PAPZIMEOS in Q4 2026 and pursuing European market entry via an ongoing EMA review. The company anticipates providing Phase II data updates for PRGN-2009 in HPV-driven cancers during the second half of 2026. R&D expenses are projected to increase as the year progresses, following a temporary dip caused by the transition of PAPZIMEOS manufacturing costs from R&D to inventory. Q1 cash used in operations included $13 million in non-recurring outflows, with significantly lower cash burn expected in Q2. The reported net loss of $7.9 million was mitigated by strong product sales, resulting in an operating loss of only $6 million for the quarter. Exceptional payer coverage has been secured, reaching an estimated 297 million lives or over 90% of insured individuals in the U.S. Management noted that current hub registration figures (approximately 400 patients) understa...

Image source: The Motley Fool. Wednesday, May 13, 2026 at 4:30 p.m. ET President and Chief Executive Officer — Helen Sabzevari Chief Commercial Officer — Phil Tennant Chief Financial Officer — Harry Thomasian Jr. Need a quote from a Motley Fool analyst? Email [email protected] Helen Sabzevari: Thank you, Steven. And thank you to all those joining us for our Q1 update call. The approval of Papzimias in August 2025 has brought a novel first-line standard-of-care treatment for adults with RRT. In 9 short months, we have witnessed tremendous progress with the first commercial therapeutic launch in the disease's history. Since last reporting in March, the launch has continued to show accelerating momentum. The early success and trajectory continues to build on this landmark achievement for the patients families, healthcare providers, the RRP Foundation, and all of those impacted by this devastating disease. I will begin by providing you with some general color around what we are seeing, and then turn the call over to Phil who will provide more specifics around commercialization. The accelerating trajectory we are seeing in revenue growth is robust. As reported in our quarterly report, Papzimias net product revenue for Q1 2026 the first full quarter of availability was $21.6 million as compared to $3.4 million in Q4 2025. Prescribers continue to add Papzimias to their practices at both major medical centers and community practices alike. Which has been a strong tailwind as we are seeing this increasing momentum continue into Q2. This is a clear signal of the high level of enthusiasm among patients and physicians resulting in significant uptake of the therapy. Why we believe we are seeing such a significant launch trajectory? First, the full approval and broad label from the FDA. There are no restrictions on the number of surgeries a patient must undergo prior to treatment with Papzimias. We are seeing this as patients are being dosed across all severities and in the extensive payer coverage we have secured. Second, the transformative clinical data based on significant efficacy durable and ongoing responses with a median duration of follow-up of 3 years. Importantly, we look forward to updating the ongoing durability data at ASCO next month. Third, the ease of administration of the drug has enabled broad and rapid uptake at not just the major medical institution, but inc...

Interested in Precigen, Inc.? Here are five stocks we like better. PAPZIMEOS drove a sharp revenue jump in Precigen’s first quarter, generating $21.6 million in net product revenue in its first full quarter of availability and lifting total company revenue to $23.3 million. The company said the launch is gaining traction with strong payer coverage and broad adoption, with more than 90% of insured lives covered and roughly 400 patients registered in its hub as of the call. Precigen reported a narrower operating loss and said it expects cash use to decline later this year, with management reiterating a path to cash flow break-even by the end of 2026 without needing to raise capital. Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025. On the company’s earnings call, President and CEO Dr. Helen Sabzevari said PAPZIMEOS generated net product revenue of $21.6 million in the first quarter, its first full quarter of availability, compared with $3.4 million in the fourth quarter of 2025. Total company revenue for the quarter was $23.3 million. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? PAPZIMEOS is approved as a first-line treatment for adults with recurrent respiratory papillomatosis, or RRP. Sabzevari said the launch has shown “accelerating momentum” across both major medical centers and community practices. “The early success and trajectory continues to build on this landmark achievement for the patients, families, healthcare providers, the Recurrent Respiratory Papillomatosis Foundation, and all of those impacted by this devastating disease,” Sabzevari said. → MP Materials Is Quietly Building a Rare Earth Powerhouse Sabzevari attributed the uptake to several factors, including the FDA’s full approval and broad label, which does not restrict treatment based on the number of surgeries a patient has previously undergone. She also cited clinical data showing efficacy and durability, ease of administration and distribution, and a recent expert position paper published in The Laryngoscope. The paper, sponsored by the RRP Foundation and authored by 16 U.S. physicians specializing in RRP, recommended PAPZIMEOS as the new standard of care and preferred first-line therapy, according to Sabzevari. → M...

On Wednesday, Precigen (NASDAQ:PGEN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://app.webinar.net/gM6Ljy5jKN3 Precigen Inc reported strong financial performance with Q1 2026 net product revenue of $21.6 million from Papcemios, up from $3.4 million in Q4 2025. The company highlighted the successful commercial launch of Papcemios, supported by FDA approval, broad payer coverage, and strong adoption in both major medical centers and community practices. Management expressed optimism about continued growth, with plans to initiate a pediatric trial for Papcemios in Q4 2026 and updates on their PRGN 2009 immunotherapy program expected later in the year. The company reported an operating loss of $6 million for the quarter, with a net loss of $7.9 million, and ended the quarter with $56.7 million in cash and equivalents. Precigen Inc anticipates achieving cash flow breakeven by the end of 2026 without needing to access additional capital markets. OPERATOR Good afternoon ladies and gentlemen and welcome to the President's first quarter 2026 financial results and Business Updates Conference Call at this time all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13, 2026 and I would now like to turn the conference over to Mr. Steven Karasim. Please go ahead sir. Steven Karasim (Moderator) Thank you Operator and thank you for all those joining us today for our Q1 2026 update call. Joining me today are Dr. Helen Sabzavari, our President and CEO, Phil Tennant, our Chief Commercial Officer, Harry Temassian, our CFO and Ratul Shah, our coo. Before we begin our prepared remarks, I remind everyone that we will be making certain forward looking statements during this call. These statements are based on our current expectations and beliefs. We encourage you to review the slide in this presentation as well as our SEC filings which include risks and uncertainties that could cause actual results to differ materially from today's forward look...

This article first appeared on GuruFocus. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Precigen Inc (NASDAQ:PGEN) reported strong revenue growth with Q1 2026 net product revenue for Papcimius reaching $21.6 million, up from $3.4 million in Q4 2025. The launch of Papcimius has been well-received, with significant uptake among both major medical centers and community practices. The FDA's full approval and broad label for Papcimius, without restrictions on the number of surgeries prior to treatment, has facilitated its rapid adoption. Comprehensive payer coverage has been achieved, with more than 90% of insured lives in the U.S. covered, supporting patient access to Papcimius. The company has a strong financial position, with $56.7 million in cash equivalents and investments, and expects to reach cash flow breakeven by the end of 2026 without needing additional funding. Despite strong revenue growth, Precigen Inc (NASDAQ:PGEN) reported an operating loss of $6 million for Q1 2026. Research and development expenses are expected to increase as the year progresses, potentially impacting future profitability. Selling, general, and administrative expenses increased by $8.7 million from the prior year's first quarter, driven by commercial activities related to Papcimius. Cash used in operations for Q1 was $43.8 million, which included $13 million of non-recurring cash outflows, indicating high operational costs. The company is not providing specific guidance for future quarters, creating uncertainty about the pace of revenue growth and financial performance. Warning! GuruFocus has detected 8 Warning Signs with PGEN. Is PGEN fairly valued? Test your thesis with our free DCF calculator. Q: Can you speak to the number of patients that have now received at least the first dose, and if you're now also seeing patients complete the full course of therapy? Also, can you provide details on the redosing trial and when we might see initial data? A: (Dr. Helen Sabzivari, CEO) We are not commenting on the specific number of patients initiated on treatment, but we are seeing progress with patients completing the full course. For the redosing trial, we have started with partial responders from previous trials and are gathering data to report later. Regarding PRGN-2009, we will report data from ongoing...

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential for substantial earnings expansion. Click here to see the full list of 185 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor cell therapy for light chain amyloidosis and immune-mediated diseases, with a market cap of $525.88 million. Operations: Revenue Segments (in millions of $): null Insider Ownership: 12.8% Earnings Growth Forecast: 63.4% p.a. Immix Biopharma is a growth-focused company with high insider ownership, currently navigating financial challenges with a reported net loss of US$10.09 million for Q1 2026. Despite this, its revenue is forecasted to grow significantly faster than the US market at 56.6% annually, driven by promising developments like NXC-201 for AL Amyloidosis. The company anticipates profitability within three years, although it has experienced substantial shareholder dilution and share price volatility recently. Get an in-depth perspective on Immix Biopharma's performance by reading our analyst estimates report here. Our valuation report here indicates Immix Biopharma may be overvalued. Simply Wall St Growth Rating: ★★★★★☆ Overview: Rumble Inc. operates a video sharing and cloud services platform across the United States, Canada, and internationally, with a market cap of approximately $2.77 billion. Operations: The company's revenue is generated from its Internet Software & Services segment, amounting to $100.62 million. Insider Ownership: 35.9% Earnings Growth Forecast: 56.8% p.a. Rumble Inc. exhibits high insider ownership and is positioned for substantial growth, with revenue forecasted to expand at 42.5% annually, outpacing the US market. Recent initiatives like the OpenClaw Starter package on Rumble Cloud highlight its innovative approach in AI infrastructure. Despite a history of volatility and fin...

GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release first quarter 2026 financial results and provide business updates on Wednesday, May 13, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations. Precigen: Advancing Medicine with Precision® Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults inclu...

The United States market has recently experienced a notable upswing, climbing 3.6% in the last week and showing a robust 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this favorable environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong confidence from those who know the business best and have vested interests in its success. Click here to see the full list of 202 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products globally with a market cap of $415.12 million. Operations: The company's revenue segment is primarily derived from its fiber management, protection, and delivery products, totaling $154.78 million. Insider Ownership: 18.3% Earnings Growth Forecast: 61.1% p.a. Clearfield's insider ownership aligns with its growth prospects, as earnings are forecast to grow significantly at 61.1% annually, outpacing the US market. Despite recent losses, Clearfield became profitable this year and expects net sales between US$160 million and US$170 million for fiscal 2026. Substantial insider buying occurred over the past three months, reflecting confidence in future performance. Recent presentations at major industry events highlight ongoing efforts to strengthen market presence and investor relations. Unlock comprehensive insights into our analysis of Clearfield stock in this growth report. In light of our recent valuation report, it seems possible that Clearfield is trading beyond its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: Alphatec Holdings, Inc. is a medical technology company that focuses on designing and developing technologies for the surgical treatment of spinal disorders, with a market cap of approximately $1.68 billion. Operations: The company generates revenue primarily from its Medical Products segment, which accounted for $764.16 million. Insider Ownership: 10.4% Earnings Growth Forecast: 56.9% p.a. Alphatec Holdings' insider ownership supports its growth trajectory, with earnings projected to grow significantly at 56.89% annually and revenue expected...

The United States market has experienced a notable upswing, climbing 4.4% in the last week and showing a robust 32% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and potential alignment with shareholder interests. Click here to see the full list of 202 stocks from our Fast Growing US Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Loar Holdings Inc. designs, manufactures, and sells aerospace and defense components for aircraft and systems both in the United States and internationally, with a market cap of $6.19 billion. Operations: The company generates revenue of $496.28 million from its aerospace and defense segments, focusing on components for aircraft and related systems in both domestic and international markets. Insider Ownership: 17.6% Earnings Growth Forecast: 24.4% p.a. Loar Holdings exhibits strong growth potential with earnings forecasted to grow significantly at 24.4% annually, outpacing the US market. Recent results show a substantial increase in net income and sales for both the fourth quarter and full year 2025, reflecting robust performance. Insider confidence is evident as more shares were bought than sold recently. However, challenges persist with low future return on equity and debt not well covered by operating cash flow. Navigate through the intricacies of Loar Holdings with our comprehensive analyst estimates report here. The valuation report we've compiled suggests that Loar Holdings' current price could be inflated. Simply Wall St Growth Rating: ★★★★★☆ Overview: Paymentus Holdings, Inc. offers cloud-based bill payment technology and solutions both in the United States and internationally, with a market cap of approximately $3.22 billion. Operations: The company generates revenue from its cloud-based bill payment technology and solutions, with services to financial companies amounting to $1.20 billion. Insider Ownership: 30.6% Earnings Growth Forecast: 24.6% p.a. Paymentus Holdings demonstrates strong growth potential with earnings expected to rise significantly at 24.6% annually, exceeding the US market...